Microcurrent Stimulation to Treat Macular Degeneration
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01790958 |
Recruitment Status
:
Completed
First Posted
: February 13, 2013
Last Update Posted
: February 13, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Retinal Diseases Stargardt's Disease Retinitis Pigmentosa |
Study Type : | Observational |
Actual Enrollment : | 50 participants |
Observational Model: | Case Control |
Time Perspective: | Retrospective |
Official Title: | An Observational, Multi-Center Phase 1 Study of the Safety and Effectiveness of Frequency Specific Microcurrent Stimulation as an Alternative Treatment for Retinal Diseases |
Study Start Date : | June 2012 |
Actual Primary Completion Date : | December 2012 |
Actual Study Completion Date : | December 2012 |

- Measure visual acuity after receiving microcurrent stimulation treatments. [ Time Frame: 6 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 50 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Ability to provide written consent and comply with follow up visits
- Age 40 years or older
- ETDRS best corrected visual acuity better than 5 letters
- History of Dry Age Relted Macular Degeneration; Retinitis Pigmentosa; Stargardt's disease
- No Anti-VEGF treatments for at least 3 months prior to study
- No new antioxidant/vitamin supplementation for at least 3 months prior to study
Exclusion Criteria:
- History of Non-Compliance with regular medical visits
- Significant media opacities (exclude NS 4+) that may interfere with assessing visual acuity
- Presence of pigment epithelial tears or rips
- Known serious allergies to fluorescein dye
- Presence of retinal neovascularization
- Any treatment with an investigation agent in the past 30 days

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01790958
United States, Hawaii | |
Hawaii Cataract Laser Institute - Hilo | |
Hilo, Hawaii, United States, 96720 | |
Retina Institute of Hawaii | |
Honolulu, Hawaii, United States, 96815 | |
Hawaii Cataract Laser Institute - Maui | |
Kahului, Hawaii, United States, 96732 | |
Hawaii Cataract Laser Institute - Kona | |
Kailua-Kona, Hawaii, United States, 96740 |
Principal Investigator: | George Papastergiou, MD | Retina Institute of Hawaii |
Responsible Party: | Retina Institute of Hawaii |
ClinicalTrials.gov Identifier: | NCT01790958 History of Changes |
Other Study ID Numbers: |
RIH 1009 |
First Posted: | February 13, 2013 Key Record Dates |
Last Update Posted: | February 13, 2013 |
Last Verified: | February 2013 |
Additional relevant MeSH terms:
Retinitis Retinitis Pigmentosa Cone-Rod Dystrophies Retinal Diseases Eye Diseases |
Eye Diseases, Hereditary Retinal Dystrophies Retinal Degeneration Genetic Diseases, Inborn |